Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Treating Inflammatory Bowel Disease by Developing Small Molecule Inhibitors of a Novel Protein Target

EF 2020-21

Résumé
Canada has one of the highest rates of inflammatory bowel disease (IBD) worldwide and this is expected to rise in the next decade. IBD is a burden on patients, healthcare and society. Despite recent advances in IBD therapies, many patients do not respond to current treatments. IBD is described as a chronic, recurrent inflammation of the gastrointestinal tract and although various genetic and environmental factors have been associated with this disease, the cause of IBD is still unknown. Numerous genes are identified as a risk factor for IBD, however, not all have been explored. One of these genetic risk factors is a gene that codes for an active, atypical dual specificity phosphatase (DUSP). DUSPs are enzymes that remove a phosphate group from a protein and many are poorly characterized. Unpublished work from our lab shows that mice lacking the gene that encodes for this DUSP are protected from developing IBD. Since this DUSP is an active enzyme, its activity can be inhibited, making it a promising therapeutic target for IBD. We hypothesize that this DUSP is critical in promoting IBD and that inhibiting the active site of the DUSP using selective and potent small molecule inhibitors may prevent and/or reduce IBD-induced pathologies. This hypothesis will be explored in two aims. The first aim is to optimize the assay conditions for identifying small molecule inhibitors. 74,000 diverse compounds will then be tested against the DUSP to test for their ability to inhibit this enzyme. In the second aim, the promising compounds will be modified until effective, lead compounds are developed. Based on the evidence that this DUSP plays a role in IBD, potent small molecule inhibitors targeting this protein will hopefully provide a promising novel treatment for IBD patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449321
Name
Ogrodnik Natalia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Treating Inflammatory Bowel Disease by Developing Small Molecule Inhibitors of a Novel Protein Target
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biochemistry; Chemical Biology; Crystallography; Drug Development; Enzymatic Assays; Immunology; Inflammatory Bowel Disease; Inhibitors; Organic Chemistry; Small Molecules
Abstract
Canada has one of the highest rates of inflammatory bowel disease (IBD) worldwide and this is expected to rise in the next decade. IBD is a burden on patients, healthcare and society. Despite recent advances in IBD therapies, many patients do not respond to current treatments. IBD is described as a chronic, recurrent inflammation of the gastrointestinal tract and although various genetic and environmental factors have been associated with this disease, the cause of IBD is still unknown. Numerous genes are identified as a risk factor for IBD, however, not all have been explored. One of these genetic risk factors is a gene that codes for an active, atypical dual specificity phosphatase (DUSP). DUSPs are enzymes that remove a phosphate group from a protein and many are poorly characterized. Unpublished work from our lab shows that mice lacking the gene that encodes for this DUSP are protected from developing IBD. Since this DUSP is an active enzyme, its activity can be inhibited, making it a promising therapeutic target for IBD. We hypothesize that this DUSP is critical in promoting IBD and that inhibiting the active site of the DUSP using selective and potent small molecule inhibitors may prevent and/or reduce IBD-induced pathologies. This hypothesis will be explored in two aims. The first aim is to optimize the assay conditions for identifying small molecule inhibitors. 74,000 diverse compounds will then be tested against the DUSP to test for their ability to inhibit this enzyme. In the second aim, the promising compounds will be modified until effective, lead compounds are developed. Based on the evidence that this DUSP plays a role in IBD, potent small molecule inhibitors targeting this protein will hopefully provide a promising novel treatment for IBD patients.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ogrodnik, Natalia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~